Identification

Name
Sparfloxacin
Accession Number
DB01208  (APRD01231)
Type
Small Molecule
Groups
Approved, Investigational
Description

Sparfloxacin is a fluoroquinolone antibiotic used in the treatment of bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.

Structure
Thumb
Synonyms
  • cis-5-Amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
  • Sparfloxacin
International/Other Brands
Zagam
Categories
UNII
Q90AGA787L
CAS number
110871-86-8
Weight
Average: 392.3998
Monoisotopic: 392.165997
Chemical Formula
C19H22F2N4O3
InChI Key
DZZWHBIBMUVIIW-DTORHVGOSA-N
InChI
InChI=1S/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12-16(14(17)21)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6,22H2,1-2H3,(H,27,28)/t8-,9+
IUPAC Name
5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
SMILES
C[C@H]1CN(C[C@@H](C)N1)C1=C(F)C(N)=C2C(=O)C(=CN(C3CC3)C2=C1F)C(O)=O

Pharmacology

Indication

For the treatment of adults with the following infections caused by susceptible strains microorganisms: community-acquired pneumonia (caused by Chlamydia pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, or Streptococcus pneumoniae) and acute bacterial exacerbations of chronic bronchitis (caused by Chlamydia pneumoniae, Enterobacter cloacae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Staphylococcus aureus, or Streptococcus pneumoniae).

Pharmacodynamics

Sparfloxacin is a synthetic fluoroquinolone broad-spectrum antimicrobial agent in the same class as ofloxacin and norfloxacin. Sparfloxacin has in vitro activity against a wide range of gram-negative and gram-positive microorganisms. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. Quinolones differ in chemical structure and mode of action from (beta)-lactam antibiotics. Quinolones may, therefore, be active against bacteria resistant to (beta)-lactam antibiotics. Although cross-resistance has been observed between sparfloxacin and other fluoroquinolones, some microorganisms resistant to other fluoroquinolones may be susceptible to sparfloxacin. In vitro tests show that the combination of sparfloxacin and rifampin is antagonistic against Staphylococcus aureus.

Mechanism of action

The bactericidal action of sparfloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.

TargetActionsOrganism
ADNA topoisomerase 4 subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
ADNA gyrase subunit A
inhibitor
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
ADNA topoisomerase 2-alpha
inhibitor
Human
Absorption

Well absorbed following oral administration with an absolute oral bioavailability of 92%. Unaffected by administration with milk or food, however concurrent administration of antacids containing magnesium hydroxide and aluminum hydroxide reduces the oral bioavailability of sparfloxacin by as much as 50%.

Volume of distribution
Not Available
Protein binding

Low plasma protein binding in serum at about 45%.

Metabolism

Hepatic. Metabolized primarily by phase II glucuronidation to form a glucuronide conjugate. Metabolism does not utilize or interfere with the cytochrome P450 enzyme system.

Route of elimination
Not Available
Half life

Mean terminal elimination half-life of 20 hours (range 16-30 hours). Prolonged in patients with renal impairment (creatinine clearance <50 mL/min).

Clearance
Not Available
Toxicity

Single doses of sparfloxacin were relatively non-toxic via the oral route of administration in mice, rats, and dogs. No deaths occurred within a 14-day post-treatment observation period at the highest oral doses tested, up to 5000 mg/kg in either rodent species, or up to 600 mg/kg in the dog. Clinical signs observed included inactivity in mice and dogs, diarrhea in both rodent species, and vomiting, salivation, and tremors in dogs.

Affected organisms
  • Enteric bacteria and other eubacteria
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the neuroexcitatory activities of Sparfloxacin.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Sparfloxacin.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Sparfloxacin.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Sparfloxacin.Experimental, Illicit
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Sparfloxacin.Approved, Investigational
AceclofenacAceclofenac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
AcemetacinAcemetacin may increase the neuroexcitatory activities of Sparfloxacin.Approved, Experimental, Investigational
AcenocoumarolSparfloxacin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe serum concentration of Sparfloxacin can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Sparfloxacin.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Sparfloxacin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may increase the neuroexcitatory activities of Sparfloxacin.Approved, Vet Approved
AdapaleneAdapalene may increase the neuroexcitatory activities of Sparfloxacin.Approved
AlbiglutideSparfloxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacAlclofenac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Sparfloxacin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Sparfloxacin.Experimental, Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenAlminoprofen may increase the neuroexcitatory activities of Sparfloxacin.Experimental
AlogliptinSparfloxacin may increase the hypoglycemic activities of Alogliptin.Approved
AloglutamolAloglutamol can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AluminiumAluminium can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ambroxol acefyllinateThe metabolism of Ambroxol acefyllinate can be decreased when combined with Sparfloxacin.Experimental, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Sparfloxacin.Approved
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Sparfloxacin.Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Amiodarone is combined with Sparfloxacin.Approved, Investigational
AmlodipineThe serum concentration of Sparfloxacin can be increased when it is combined with Amlodipine.Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Sparfloxacin.Approved, Investigational, Withdrawn
AndrographolideAndrographolide may increase the neuroexcitatory activities of Sparfloxacin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Sparfloxacin.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Sparfloxacin.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Sparfloxacin.Investigational
AnisodamineAnisodamine may increase the neuroexcitatory activities of Sparfloxacin.Investigational
AntipyrineAntipyrine may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
ApalutamideThe serum concentration of Sparfloxacin can be decreased when it is combined with Apalutamide.Approved, Investigational
ApocyninApocynin may increase the neuroexcitatory activities of Sparfloxacin.Investigational
ApremilastApremilast may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Sparfloxacin.Investigational
AzapropazoneAzapropazone may increase the neuroexcitatory activities of Sparfloxacin.Withdrawn
AzelastineAzelastine may increase the neuroexcitatory activities of Sparfloxacin.Approved
BalsalazideBalsalazide may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Sparfloxacin.Investigational
Beclomethasone dipropionateThe risk or severity of tendinopathy can be increased when Beclomethasone dipropionate is combined with Sparfloxacin.Approved, Investigational
BendazacBendazac may increase the neuroexcitatory activities of Sparfloxacin.Experimental
BenorilateBenorilate may increase the neuroexcitatory activities of Sparfloxacin.Experimental
BenoxaprofenBenoxaprofen may increase the neuroexcitatory activities of Sparfloxacin.Withdrawn
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Sparfloxacin.Approved
BenzydamineBenzydamine may increase the neuroexcitatory activities of Sparfloxacin.Approved
Benzyl alcoholThe serum concentration of Sparfloxacin can be increased when it is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Bepridil is combined with Sparfloxacin.Approved, Withdrawn
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Sparfloxacin.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Sparfloxacin.Approved, Investigational
BevoniumBevonium may increase the neuroexcitatory activities of Sparfloxacin.Experimental
Bismuth subcitrate potassiumBismuth Subcitrate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BromfenacBromfenac may increase the neuroexcitatory activities of Sparfloxacin.Approved
BromocriptineSparfloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Sparfloxacin.Approved
BucillamineBucillamine may increase the neuroexcitatory activities of Sparfloxacin.Investigational
BudesonideThe risk or severity of tendinopathy can be increased when Budesonide is combined with Sparfloxacin.Approved
BufexamacBufexamac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Experimental
BumadizoneBumadizone may increase the neuroexcitatory activities of Sparfloxacin.Experimental
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Sparfloxacin.Approved
CaffeineThe metabolism of Caffeine can be decreased when combined with Sparfloxacin.Approved
Calcium AcetateCalcium Acetate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium ChlorideCalcium Chloride can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium CitrateCalcium Citrate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium glubionateCalcium glubionate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium GluceptateCalcium Gluceptate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium gluconateCalcium gluconate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Calcium lactateCalcium lactate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
Calcium lactate gluconateCalcium lactate gluconate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium levulinateCalcium levulinate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Calcium pangamateCalcium pangamate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Calcium PhosphateCalcium Phosphate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium silicateCalcium silicate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CanagliflozinSparfloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
Carbaspirin calciumCarbaspirin calcium may increase the neuroexcitatory activities of Sparfloxacin.Experimental, Investigational
CarprofenCarprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Sparfloxacin can be increased when it is combined with Carvedilol.Approved, Investigational
CaseinCasein can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CastanospermineCastanospermine may increase the neuroexcitatory activities of Sparfloxacin.Experimental
CelecoxibCelecoxib may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Sparfloxacin.Approved
ChloroquineChloroquine may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Sparfloxacin.Approved
ChlorpropamideSparfloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the neuroexcitatory activities of Sparfloxacin.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Sparfloxacin.Approved, Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Sparfloxacin.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Sparfloxacin.Approved, Investigational
ClemastineThe risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Clemastine.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Sparfloxacin.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Sparfloxacin.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Sparfloxacin.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Sparfloxacin.Approved
ClonixinClonixin may increase the neuroexcitatory activities of Sparfloxacin.Approved
ClorindioneSparfloxacin may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Sparfloxacin.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Sparfloxacin.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Sparfloxacin.Approved, Investigational
CurcuminCurcumin may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Sparfloxacin.Approved, Investigational
CyclosporineThe serum concentration of Sparfloxacin can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Sparfloxacin.Experimental
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Sparfloxacin.Approved
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Sparfloxacin.Approved, Investigational
DelamanidSparfloxacin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Sparfloxacin.Approved
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Sparfloxacin.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Sparfloxacin.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Sparfloxacin.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Sparfloxacin.Experimental, Vet Approved
DeutetrabenazineSparfloxacin may increase the QTc-prolonging activities of Deutetrabenazine.Approved, Investigational
DexamethasoneThe risk or severity of tendinopathy can be increased when Dexamethasone is combined with Sparfloxacin.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Sparfloxacin.Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sparfloxacin.Approved
DexniguldipineThe serum concentration of Sparfloxacin can be increased when it is combined with Dexniguldipine.Experimental
DexverapamilThe serum concentration of Sparfloxacin can be increased when it is combined with Dexverapamil.Experimental
DiclofenacDiclofenac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Vet Approved
DicoumarolSparfloxacin may increase the anticoagulant activities of Dicoumarol.Approved
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Sparfloxacin.Approved
DifenpiramideDifenpiramide may increase the neuroexcitatory activities of Sparfloxacin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Sparfloxacin.Approved
DiflunisalDiflunisal may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Sparfloxacin.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Sparfloxacin.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Sparfloxacin.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Sparfloxacin.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Sparfloxacin.Approved
DiltiazemThe serum concentration of Sparfloxacin can be increased when it is combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Sparfloxacin.Approved
DiphenadioneSparfloxacin may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Sparfloxacin.Approved, Investigational
DisopyramideSparfloxacin may increase the hypoglycemic activities of Disopyramide.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sparfloxacin.Approved, Investigational
DoxazosinThe serum concentration of Sparfloxacin can be increased when it is combined with Doxazosin.Approved
DoxylamineThe risk or severity of QTc prolongation can be increased when Doxylamine is combined with Sparfloxacin.Approved, Vet Approved
DroxicamDroxicam may increase the neuroexcitatory activities of Sparfloxacin.Withdrawn
DulaglutideSparfloxacin may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuvelisibDuvelisib may increase the neuroexcitatory activities of Sparfloxacin.Investigational
DyphyllineThe metabolism of Dyphylline can be decreased when combined with Sparfloxacin.Approved
E-6201E-6201 may increase the neuroexcitatory activities of Sparfloxacin.Investigational
EmopamilThe serum concentration of Sparfloxacin can be increased when it is combined with Emopamil.Experimental
EmpagliflozinSparfloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpirizoleEpirizole may increase the neuroexcitatory activities of Sparfloxacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Sparfloxacin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Sparfloxacin.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Sparfloxacin.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Sparfloxacin.Approved
EthenzamideEthenzamide may increase the neuroexcitatory activities of Sparfloxacin.Experimental
Ethyl biscoumacetateSparfloxacin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
EtoricoxibEtoricoxib may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
ExenatideSparfloxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
ExisulindExisulind may increase the neuroexcitatory activities of Sparfloxacin.Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Sparfloxacin.Approved
FelbinacFelbinac may increase the neuroexcitatory activities of Sparfloxacin.Experimental
FelodipineThe serum concentration of Sparfloxacin can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may increase the neuroexcitatory activities of Sparfloxacin.Approved
FenoprofenFenoprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved
FentanylThe serum concentration of Sparfloxacin can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may increase the neuroexcitatory activities of Sparfloxacin.Experimental
FeprazoneFeprazone may increase the neuroexcitatory activities of Sparfloxacin.Experimental
Ferric CarboxymaltoseThe serum concentration of Sparfloxacin can be decreased when it is combined with Ferric Carboxymaltose.Approved
Ferric pyrophosphateThe serum concentration of Sparfloxacin can be decreased when it is combined with Ferric pyrophosphate.Experimental
Ferulic acidFerulic acid may increase the neuroexcitatory activities of Sparfloxacin.Experimental
FloctafenineFloctafenine may increase the neuroexcitatory activities of Sparfloxacin.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Sparfloxacin.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Sparfloxacin.Approved, Investigational
FluindioneSparfloxacin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Sparfloxacin.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Sparfloxacin.Approved, Investigational
FlunixinFlunixin may increase the neuroexcitatory activities of Sparfloxacin.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the neuroexcitatory activities of Sparfloxacin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Sparfloxacin.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Sparfloxacin.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Sparfloxacin.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Sparfloxacin.Approved, Investigational
FluoxetineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Sparfloxacin.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Sparfloxacin.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Sparfloxacin.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Sparfloxacin.Approved
FlurbiprofenFlurbiprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Sparfloxacin.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Sparfloxacin.Approved
Fluticasone propionateThe risk or severity of tendinopathy can be increased when Fluticasone propionate is combined with Sparfloxacin.Approved
FluvoxamineThe serum concentration of Sparfloxacin can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Sparfloxacin.Approved, Investigational, Withdrawn
GallopamilThe serum concentration of Sparfloxacin can be increased when it is combined with Gallopamil.Investigational
GanciclovirThe metabolism of Ganciclovir can be decreased when combined with Sparfloxacin.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Sparfloxacin.Experimental
GliclazideSparfloxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be increased when used in combination with Sparfloxacin.Approved
GlipizideThe therapeutic efficacy of Glipizide can be increased when used in combination with Sparfloxacin.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be increased when used in combination with Sparfloxacin.Approved
GlycerinThe serum concentration of Sparfloxacin can be increased when it is combined with Glycerin.Approved, Investigational
GoserelinThe risk or severity of QTc prolongation can be increased when Goserelin is combined with Sparfloxacin.Approved
Gramicidin DThe serum concentration of Sparfloxacin can be increased when it is combined with Gramicidin D.Approved
GuacetisalGuacetisal may increase the neuroexcitatory activities of Sparfloxacin.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Sparfloxacin.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Sparfloxacin.Investigational
HigenamineHigenamine may increase the neuroexcitatory activities of Sparfloxacin.Investigational
HydrocortisoneThe risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Sparfloxacin.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of tendinopathy can be increased when Hydrocortisone acetate is combined with Sparfloxacin.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of tendinopathy can be increased when Hydrocortisone butyrate is combined with Sparfloxacin.Approved, Vet Approved
HydrotalciteHydrotalcite can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Sparfloxacin.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sparfloxacin.Approved, Investigational
IbuprofenThe serum concentration of Sparfloxacin can be increased when it is combined with Ibuprofen.Approved
IbuproxamIbuproxam may increase the neuroexcitatory activities of Sparfloxacin.Withdrawn
IcatibantIcatibant may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
Imidazole salicylateImidazole salicylate may increase the neuroexcitatory activities of Sparfloxacin.Experimental
IndobufenIndobufen may increase the neuroexcitatory activities of Sparfloxacin.Investigational
IndomethacinIndomethacin may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
IndoprofenIndoprofen may increase the neuroexcitatory activities of Sparfloxacin.Withdrawn
Insulin AspartSparfloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirSparfloxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be increased when used in combination with Sparfloxacin.Approved
Insulin GlulisineSparfloxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be increased when used in combination with Sparfloxacin.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be increased when used in combination with Sparfloxacin.Approved
IronThe serum concentration of Sparfloxacin can be decreased when it is combined with Iron.Approved
Iron DextranThe serum concentration of Sparfloxacin can be decreased when it is combined with Iron Dextran.Approved, Vet Approved
Iron saccharateThe serum concentration of Sparfloxacin can be decreased when it is combined with Iron saccharate.Approved
IsavuconazoleThe serum concentration of Sparfloxacin can be increased when it is combined with Isavuconazole.Approved, Investigational
IsoxicamIsoxicam may increase the neuroexcitatory activities of Sparfloxacin.Withdrawn
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Sparfloxacin.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Sparfloxacin.Investigational
KebuzoneKebuzone may increase the neuroexcitatory activities of Sparfloxacin.Experimental
KetoprofenKetoprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Vet Approved
KetorolacKetorolac may increase the neuroexcitatory activities of Sparfloxacin.Approved
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Sparfloxacin.Experimental
Lanthanum carbonateThe serum concentration of Sparfloxacin can be decreased when it is combined with Lanthanum carbonate.Approved
LeflunomideLeflunomide may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sparfloxacin.Approved, Investigational
LidocaineThe serum concentration of Sparfloxacin can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiraglutideSparfloxacin may increase the hypoglycemic activities of Liraglutide.Approved
LisofyllineLisofylline may increase the neuroexcitatory activities of Sparfloxacin.Investigational
LomerizineThe serum concentration of Sparfloxacin can be increased when it is combined with Lomerizine.Experimental
LonazolacLonazolac may increase the neuroexcitatory activities of Sparfloxacin.Experimental
LoperamideThe serum concentration of Sparfloxacin can be increased when it is combined with Loperamide.Approved
LoratadineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Sparfloxacin.Approved, Investigational
LornoxicamLornoxicam may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
LosartanThe serum concentration of Sparfloxacin can be increased when it is combined with Losartan.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Sparfloxacin.Approved
LoxoprofenLoxoprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
LumacaftorThe serum concentration of Sparfloxacin can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
MacimorelinSparfloxacin may increase the QTc-prolonging activities of Macimorelin.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateThe serum concentration of Sparfloxacin can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateMagnesium sulfate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
MasoprocolMasoprocol may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Sparfloxacin.Investigational
MecaserminSparfloxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the neuroexcitatory activities of Sparfloxacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Sparfloxacin.Approved
Mefenamic acidMefenamic acid may increase the neuroexcitatory activities of Sparfloxacin.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Sparfloxacin.Vet Approved
MeloxicamMeloxicam may increase the neuroexcitatory activities of Sparfloxacin.Approved, Vet Approved
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Sparfloxacin.Approved, Vet Approved
MesalazineMesalazine may increase the neuroexcitatory activities of Sparfloxacin.Approved
MetamizoleMetamizole may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be increased when used in combination with Sparfloxacin.Approved
MethylprednisoloneThe risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Sparfloxacin.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Sparfloxacin.Experimental
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Sparfloxacin.Approved, Investigational
MibefradilThe serum concentration of Sparfloxacin can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Sparfloxacin can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MifepristoneSparfloxacin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolSparfloxacin may increase the hypoglycemic activities of Miglitol.Approved
MizoribineMizoribine may increase the neuroexcitatory activities of Sparfloxacin.Investigational
MofebutazoneMofebutazone may increase the neuroexcitatory activities of Sparfloxacin.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Sparfloxacin.Approved, Vet Approved
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Sparfloxacin.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Sparfloxacin.Approved
NabumetoneNabumetone may increase the neuroexcitatory activities of Sparfloxacin.Approved
NafamostatNafamostat may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
NaftifineNaftifine may increase the neuroexcitatory activities of Sparfloxacin.Approved
NaproxenNaproxen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Vet Approved
NateglinideSparfloxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Sparfloxacin.Investigational
NepafenacNepafenac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Sparfloxacin.Approved, Investigational
NifenazoneNifenazone may increase the neuroexcitatory activities of Sparfloxacin.Experimental
Niflumic AcidNiflumic Acid may increase the neuroexcitatory activities of Sparfloxacin.Approved
NiguldipineThe serum concentration of Sparfloxacin can be increased when it is combined with Niguldipine.Experimental
NimesulideNimesulide may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Sparfloxacin can be increased when it is combined with Nimodipine.Approved, Investigational
NisoldipineThe serum concentration of Sparfloxacin can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Sparfloxacin can be increased when it is combined with Nitrendipine.Approved, Investigational
NitroaspirinNitroaspirin may increase the neuroexcitatory activities of Sparfloxacin.Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Sparfloxacin.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Sparfloxacin.Investigational
OlopatadineOlopatadine may increase the neuroexcitatory activities of Sparfloxacin.Approved
OlsalazineOlsalazine may increase the neuroexcitatory activities of Sparfloxacin.Approved
OmeprazoleThe serum concentration of Sparfloxacin can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Ondansetron is combined with Sparfloxacin.Approved
OrgoteinOrgotein may increase the neuroexcitatory activities of Sparfloxacin.Vet Approved
OuabainOuabain may decrease the cardiotoxic activities of Sparfloxacin.Approved
OxaprozinOxaprozin may increase the neuroexcitatory activities of Sparfloxacin.Approved
OxyphenbutazoneOxyphenbutazone may increase the neuroexcitatory activities of Sparfloxacin.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sparfloxacin.Approved, Vet Approved
PalmidrolPalmidrol may increase the neuroexcitatory activities of Sparfloxacin.Experimental, Nutraceutical
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Sparfloxacin.Approved
ParecoxibParecoxib may increase the neuroexcitatory activities of Sparfloxacin.Approved
ParoxetineThe risk or severity of QTc prolongation can be increased when Paroxetine is combined with Sparfloxacin.Approved, Investigational
ParthenolideParthenolide may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
PentamidineSparfloxacin may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PeruvosidePeruvoside may decrease the cardiotoxic activities of Sparfloxacin.Experimental
PhenindioneSparfloxacin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Sparfloxacin.Approved
PhenprocoumonSparfloxacin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the neuroexcitatory activities of Sparfloxacin.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sparfloxacin.Approved
PimecrolimusPimecrolimus may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
PioglitazoneSparfloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirfenidonePirfenidone may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
PiroxicamPiroxicam may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
PirprofenPirprofen may increase the neuroexcitatory activities of Sparfloxacin.Experimental
PitolisantThe risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Pitolisant.Approved, Investigational
PramlintideSparfloxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenPranoprofen may increase the neuroexcitatory activities of Sparfloxacin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Sparfloxacin.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Sparfloxacin.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Sparfloxacin.Approved, Investigational
PrednisoloneThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Sparfloxacin.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Sparfloxacin.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Sparfloxacin.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Sparfloxacin can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinProglumetacin may increase the neuroexcitatory activities of Sparfloxacin.Experimental
PromethazineThe risk or severity of QTc prolongation can be increased when Promethazine is combined with Sparfloxacin.Approved, Investigational
PropacetamolPropacetamol may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Sparfloxacin.Approved
PropyphenazonePropyphenazone may increase the neuroexcitatory activities of Sparfloxacin.Experimental
ProquazoneProquazone may increase the neuroexcitatory activities of Sparfloxacin.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Sparfloxacin.Experimental
PTC299PTC299 may increase the neuroexcitatory activities of Sparfloxacin.Investigational
QuetiapineThe risk or severity of QTc prolongation can be increased when Quetiapine is combined with Sparfloxacin.Approved
QuinaprilQuinapril can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
QuinineSparfloxacin may increase the hypoglycemic activities of Quinine.Approved
RanitidineThe serum concentration of Sparfloxacin can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Sparfloxacin can be increased when it is combined with Ranolazine.Approved, Investigational
RepaglinideSparfloxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ResveratrolResveratrol may increase the neuroexcitatory activities of Sparfloxacin.Approved, Experimental, Investigational
RibociclibThe risk or severity of QTc prolongation can be increased when Ribociclib is combined with Sparfloxacin.Approved, Investigational
RifampicinThe serum concentration of Sparfloxacin can be increased when it is combined with Rifampicin.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Sparfloxacin.Approved
RofecoxibRofecoxib may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational, Withdrawn
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be increased when used in combination with Sparfloxacin.Approved, Investigational
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Sparfloxacin.Approved, Vet Approved
SalicylamideSalicylamide may increase the neuroexcitatory activities of Sparfloxacin.Approved
Salicylic acidSalicylic acid may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Sparfloxacin.Approved
SalsalateSalsalate may increase the neuroexcitatory activities of Sparfloxacin.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be increased when used in combination with Sparfloxacin.Approved
SemapimodSemapimod may increase the neuroexcitatory activities of Sparfloxacin.Investigational
SeratrodastSeratrodast may increase the neuroexcitatory activities of Sparfloxacin.Approved
SerrapeptaseSerrapeptase may increase the neuroexcitatory activities of Sparfloxacin.Investigational
SevelamerSevelamer can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SitagliptinThe therapeutic efficacy of Sitagliptin can be increased when used in combination with Sparfloxacin.Approved, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SRT501SRT501 may increase the neuroexcitatory activities of Sparfloxacin.Investigational
Strontium ranelateThe serum concentration of Sparfloxacin can be decreased when it is combined with Strontium ranelate.Approved, Withdrawn
SucralfateThe serum concentration of Sparfloxacin can be decreased when it is combined with Sucralfate.Approved
SulfadiazineSparfloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleSparfloxacin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineSulfasalazine may increase the neuroexcitatory activities of Sparfloxacin.Approved
SulfisoxazoleSparfloxacin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacSulindac may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SunitinibSparfloxacin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenSuprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the neuroexcitatory activities of Sparfloxacin.Experimental
TarenflurbilTarenflurbil may increase the neuroexcitatory activities of Sparfloxacin.Investigational
TenidapTenidap may increase the neuroexcitatory activities of Sparfloxacin.Experimental
TenoxicamTenoxicam may increase the neuroexcitatory activities of Sparfloxacin.Approved
TepoxalinTepoxalin may increase the neuroexcitatory activities of Sparfloxacin.Vet Approved
TeriflunomideTeriflunomide may increase the neuroexcitatory activities of Sparfloxacin.Approved
TerodilineThe risk or severity of QTc prolongation can be increased when Sparfloxacin is combined with Terodiline.Experimental
TetrandrineThe serum concentration of Sparfloxacin can be increased when it is combined with Tetrandrine.Experimental
TheophyllineThe metabolism of Theophylline can be decreased when combined with Sparfloxacin.Approved
Tiaprofenic acidTiaprofenic acid may increase the neuroexcitatory activities of Sparfloxacin.Approved
TinoridineTinoridine may increase the neuroexcitatory activities of Sparfloxacin.Investigational
TioclomarolSparfloxacin may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Sparfloxacin.Approved, Withdrawn
TolazamideSparfloxacin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideSparfloxacin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidTolfenamic Acid may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
TolmetinTolmetin may increase the neuroexcitatory activities of Sparfloxacin.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Sparfloxacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Sparfloxacin.Approved, Vet Approved
TribenosideTribenoside may increase the neuroexcitatory activities of Sparfloxacin.Experimental
TriptolideTriptolide may increase the neuroexcitatory activities of Sparfloxacin.Investigational
Trolamine salicylateTrolamine salicylate may increase the neuroexcitatory activities of Sparfloxacin.Approved
TromethamineTromethamine can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Sparfloxacin.Approved
ValaciclovirThe metabolism of Valaciclovir can be decreased when combined with Sparfloxacin.Approved, Investigational
ValdecoxibValdecoxib may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of QTc prolongation can be increased when Valproic Acid is combined with Sparfloxacin.Approved, Investigational
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Sparfloxacin.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Sparfloxacin.Approved
VenlafaxineThe risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Sparfloxacin.Approved
VerapamilThe serum concentration of Sparfloxacin can be increased when it is combined with Verapamil.Approved
WarfarinSparfloxacin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
ZileutonZileuton may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational, Withdrawn
Zinc acetateZinc acetate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Zinc chlorideZinc chloride can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
Zinc oxideZinc oxide can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ZomepiracZomepirac may increase the neuroexcitatory activities of Sparfloxacin.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Guillaume Conrath, "Solution of sparfloxacin, its preparation and salt of which it is composed." U.S. Patent US5478829, issued May, 1987.

US5478829
General References
Not Available
External Links
Human Metabolome Database
HMDB0015339
KEGG Drug
D00590
KEGG Compound
C07662
PubChem Compound
60464
PubChem Substance
46506453
ChemSpider
54517
BindingDB
50366822
ChEBI
9212
ChEMBL
CHEMBL850
Therapeutic Targets Database
DAP000161
PharmGKB
PA451472
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Sparfloxacin
ATC Codes
J01MA09 — Sparfloxacin
FDA label
Download (13.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentOsteomyelitis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US4795751No1993-02-042010-02-04Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityPractically insolubleNot Available
logP2.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.113 mg/mLALOGPS
logP-0.07ALOGPS
logP-0.043ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)5.75ChemAxon
pKa (Strongest Basic)8.79ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area98.9 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity101.69 m3·mol-1ChemAxon
Polarizability38.98 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9845
Blood Brain Barrier-0.967
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.8118
P-glycoprotein inhibitor INon-inhibitor0.9345
P-glycoprotein inhibitor IINon-inhibitor0.9183
Renal organic cation transporterNon-inhibitor0.8154
CYP450 2C9 substrateNon-substrate0.8794
CYP450 2D6 substrateNon-substrate0.8787
CYP450 3A4 substrateNon-substrate0.6465
CYP450 1A2 substrateNon-inhibitor0.82
CYP450 2C9 inhibitorNon-inhibitor0.84
CYP450 2D6 inhibitorNon-inhibitor0.89
CYP450 2C19 inhibitorNon-inhibitor0.8339
CYP450 3A4 inhibitorNon-inhibitor0.85
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7377
Ames testAMES toxic0.6341
CarcinogenicityNon-carcinogens0.8044
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.9265 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.967
hERG inhibition (predictor II)Non-inhibitor0.7961
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - DI-ESI-qTof , NegativeLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-1269000000-99d4bb9a3315f1f23139
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000j-0922000000-9b26b987caa87b8a13af

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / N-arylpiperazines / Aminoquinolines and derivatives / Haloquinolines / Hydroquinolones / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / Aryl fluorides / Benzenoids
show 13 more
Substituents
Quinoline-3-carboxylic acid / Fluoroquinolone / N-arylpiperazine / Aminoquinoline / Haloquinoline / Dihydroquinolone / Dihydroquinoline / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives / Dialkylarylamine
show 30 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
N-arylpiperazine, quinolone antibiotic, fluoroquinolone antibiotic, quinolone, quinolinemonocarboxylic acid (CHEBI:9212)

Targets

Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
Topoisomerase IV is essential for chromosome segregation. It relaxes supercoiled DNA. Performs the decatenation events required during the replication of a circular DNA molecule.
Gene Name
parC
Uniprot ID
P43702
Uniprot Name
DNA topoisomerase 4 subunit A
Molecular Weight
83366.24 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Galbraith KM, Ng AC, Eggers BJ, Kuchel CR, Eggers CH, Samuels DS: parC mutations in fluoroquinolone-resistant Borrelia burgdorferi. Antimicrob Agents Chemother. 2005 Oct;49(10):4354-7. [PubMed:16189120]
  4. Oyamada Y, Ito H, Fujimoto K, Asada R, Niga T, Okamoto R, Inoue M, Yamagishi J: Combination of known and unknown mechanisms confers high-level resistance to fluoroquinolones in Enterococcus faecium. J Med Microbiol. 2006 Jun;55(Pt 6):729-36. [PubMed:16687591]
  5. Pan XS, Yague G, Fisher LM: Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins. Antimicrob Agents Chemother. 2001 Nov;45(11):3140-7. [PubMed:11600369]
Kind
Protein
Organism
Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Dna topoisomerase type ii (atp-hydrolyzing) activity
Specific Function
DNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, inc...
Gene Name
gyrA
Uniprot ID
P43700
Uniprot Name
DNA gyrase subunit A
Molecular Weight
97817.145 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Schmitz FJ, Hofmann B, Hansen B, Scheuring S, Luckefahr M, Klootwijk M, Verhoef J, Fluit A, Heinz HP, Kohrer K, Jones ME: Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother. 1998 Apr;41(4):481-4. [PubMed:9598779]
  4. Taba H, Kusano N: Sparfloxacin resistance in clinical isolates of Streptococcus pneumoniae: involvement of multiple mutations in gyrA and parC genes. Antimicrob Agents Chemother. 1998 Sep;42(9):2193-6. [PubMed:9736534]
  5. Fukuda H, Hori S, Hiramatsu K: Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother. 1998 Aug;42(8):1917-22. [PubMed:9687384]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Ubiquitin binding
Specific Function
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segr...
Gene Name
TOP2A
Uniprot ID
P11388
Uniprot Name
DNA topoisomerase 2-alpha
Molecular Weight
174383.88 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Skidmore L. (2017). Mosby's Nursing Drug Reference (30th ed.). Elsevier. [ISBN:978-0-323-44826-0]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Symporter activity
Specific Function
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cat...
Gene Name
SLC22A5
Uniprot ID
O76082
Uniprot Name
Solute carrier family 22 member 5
Molecular Weight
62751.08 Da
References
  1. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A: Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. [PubMed:10525100]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Sasabe H, Tsuji A, Sugiyama Y: Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats. J Pharmacol Exp Ther. 1998 Mar;284(3):1033-9. [PubMed:9495864]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Naruhashi K, Tamai I, Inoue N, Muraoka H, Sai Y, Suzuki N, Tsuji A: Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein. J Pharm Pharmacol. 2001 May;53(5):699-709. [PubMed:11370709]
  2. Cormet-Boyaka E, Huneau JF, Mordrelle A, Boyaka PN, Carbon C, Rubinstein E, Tome D: Secretion of sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors. Antimicrob Agents Chemother. 1998 Oct;42(10):2607-11. [PubMed:9756763]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 14:06